{
    "id": 3744,
    "name": "cervical squamous cell carcinoma",
    "source": "DOID",
    "definition": "A cervix carcinoma that has_material_basis_in squamous cells of the cervix. [url:http\\://en.wikipedia.org/wiki/Squamous-cell_carcinoma, url:http\\://www.cancer.gov/dictionary?CdrID=752829]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3744",
    "evidence": [
        {
            "id": 11830,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with cervical squamous cell carcinoma harboring PIK3CA E542K demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 6168,
                "therapyName": "Gemcitabine + LY2780301",
                "synonyms": null
            },
            "indication": {
                "id": 3744,
                "name": "cervical squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9864,
                    "pubMedId": 28750271,
                    "title": "Safety, tolerability\u00a0and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28750271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14158,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with squamous cell carcinoma of the cervix harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).",
            "molecularProfile": {
                "id": 10071,
                "profileName": "FGFR3 - TACC3"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 3744,
                "name": "cervical squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11482,
                    "pubMedId": null,
                    "title": "Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.",
                    "url": "https://meetinglibrary.asco.org/record/161579/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01101451",
            "title": "Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01351103",
            "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                },
                {
                    "id": 7468,
                    "therapyName": "LGK974 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02187848",
            "title": "Evaluation of SAR408701 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7225,
                    "therapyName": "SAR408701",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02257528",
            "title": "Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02348398",
            "title": "Phase II Study of Pazopanib and Topotecan in Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1469,
                    "therapyName": "Pazopanib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02558348",
            "title": "Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 980,
                    "therapyName": "Anlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584478",
            "title": "Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7370,
                    "therapyName": "Anlotinib + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646319",
            "title": "Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3380,
                    "therapyName": "Nab-Rapamycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834013",
            "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02853604",
            "title": "Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3090,
                    "therapyName": "ADXS11-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03108495",
            "title": "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6772,
                    "therapyName": "LN-145",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03357757",
            "title": "Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6769,
                    "therapyName": "Avelumab + Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03367871",
            "title": "Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6522,
                    "therapyName": "Cisplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03438396",
            "title": "A Trial of Tisotumab Vedotin in Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6113,
                    "therapyName": "Tisotumab Vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03495882",
            "title": "Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8614,
                    "therapyName": "AGEN1884 + AGEN2034",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03635567",
            "title": "Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2512,
                    "therapyName": "Bevacizumab + Cisplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1812,
                    "therapyName": "Cisplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 6522,
                    "therapyName": "Cisplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2104,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7515,
                    "therapyName": "Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03644342",
            "title": "Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03738228",
            "title": "Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7491,
                    "therapyName": "Atezolizumab + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03786081",
            "title": "Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7729,
                    "therapyName": "Bevacizumab + Tisotumab Vedotin",
                    "synonyms": null
                },
                {
                    "id": 7728,
                    "therapyName": "Carboplatin + Tisotumab Vedotin",
                    "synonyms": null
                },
                {
                    "id": 7727,
                    "therapyName": "Pembrolizumab + Tisotumab Vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03830866",
            "title": "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 6903,
                    "therapyName": "Cisplatin + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 7781,
                    "therapyName": "Carboplatin + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03894215",
            "title": "Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5693,
                    "therapyName": "AGEN2034",
                    "synonyms": null
                },
                {
                    "id": 8614,
                    "therapyName": "AGEN1884 + AGEN2034",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03894618",
            "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8683,
                    "therapyName": "SL-279252",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04246489",
            "title": "Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04300647",
            "title": "A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 4269,
                    "therapyName": "Atezolizumab + MTIG7192A",
                    "synonyms": null
                }
            ]
        }
    ]
}